ad imagine trial, page-50

A positive amyloid PET scan in itself is not definitive for Alzheimer's disease; this test is a diagnostic tool to determine whether or not there is beta-amyloid in the brain to help increase the clinical certainty of diagnosis. The appropriate use criteria help define who should be tested and who should order and/or read the test.
in patients who are age 65 or older who meet standard definitions and tests for AD, indicating a positive PET scan would provide little added value
to the diagnosis.
• In asymptomatic patients or those with a cognitive complaint with no clinical confirmation of impairment.
• To determine dementia severity.
• In patients who request testing solely based on a family history of dementia or presence of other risk factors for AD, such as the ApoE-e4 gene.
• As a substitute for genetic testing for mutations that cause AD.
• For non-medical reasons, such as insurance, legal, or employment decisions.myloid PET results do not establish a diagnosis of AD or other cognitive disorders. According to the FDA, it is “an adjunct to other diagnostic evaluations” — an additional tool to give physicians additional information to help clarify an otherwise unclear diagnosis. Amyloid PET imaging should only be used as part of a clinical workup in limited situations as determined by a dementia expert.